These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18720537)

  • 1. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis.
    Tellez-Avila FI; Sanchez-Avila F; García-Saenz-de-Sicilia M; Chavez-Tapia NC; Franco-Guzman AM; Lopez-Arce G; Cerda-Contreras E; Uribe M
    World J Gastroenterol; 2008 Aug; 14(30):4771-5. PubMed ID: 18720537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is cryptogenic cirrhosis different from NASH cirrhosis?
    Thuluvath PJ; Kantsevoy S; Thuluvath AJ; Savva Y
    J Hepatol; 2018 Mar; 68(3):519-525. PubMed ID: 29162389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study.
    Poonawala A; Nair SP; Thuluvath PJ
    Hepatology; 2000 Oct; 32(4 Pt 1):689-92. PubMed ID: 11003611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.
    Caldwell SH; Oelsner DH; Iezzoni JC; Hespenheide EE; Battle EH; Driscoll CJ
    Hepatology; 1999 Mar; 29(3):664-9. PubMed ID: 10051466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethnic differences in the prevalence of cryptogenic cirrhosis.
    Browning JD; Kumar KS; Saboorian MH; Thiele DL
    Am J Gastroenterol; 2004 Feb; 99(2):292-8. PubMed ID: 15046220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics of patients with cryptogenic liver cirrhosis in Okinawa, Japan.
    Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Yamashiro T; Maeshiro T; Kobashigawa K; Kinjo F; Saito A
    Hepatogastroenterology; 2003; 50(54):2005-8. PubMed ID: 14696453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence, aetiology and related comorbidities of cirrhosis: a Swedish population-based cohort study.
    Vaz J; Eriksson B; Strömberg U; Buchebner D; Midlöv P
    BMC Gastroenterol; 2020 Apr; 20(1):84. PubMed ID: 32245414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Characterization of Gastric Antral Vascular Ectasia: A Potential Manifestation of the Metabolic Syndrome.
    Smith E; Tekola B; Patrie J; Cornella S; Caldwell S
    Am J Med; 2016 Dec; 129(12):1329.e19-1329.e23. PubMed ID: 27476085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
    Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
    Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis.
    Ratziu V; Bonyhay L; Di Martino V; Charlotte F; Cavallaro L; Sayegh-Tainturier MH; Giral P; Grimaldi A; Opolon P; Poynard T
    Hepatology; 2002 Jun; 35(6):1485-93. PubMed ID: 12029634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevalence and clinical features of non-alcoholic steatohepatitis in a hypertensive population].
    García-Carretero R; Barquero-Pérez O; Mora-Jiménez I; Soguero-Ruiz C; Goya-Esteban R; Rodríguez-Castro C; Ramos-López J
    Hipertens Riesgo Vasc; 2019; 36(3):130-136. PubMed ID: 30655210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.
    Younossi Z; Stepanova M; Sanyal AJ; Harrison SA; Ratziu V; Abdelmalek MF; Diehl AM; Caldwell S; Shiffman ML; Schall RA; McColgan B; Subramanian GM; Myers RP; Muir A; Afdhal NH; Bosch J; Goodman Z
    J Hepatol; 2018 Dec; 69(6):1365-1370. PubMed ID: 30144554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical presentation and prevalence of spontaneous bacterial peritonitis in patients with cryptogenic cirrhosis and features of metabolic syndrome.
    Sorrentino P; Tarantino G; Conca P; Perrella A; Perrella O
    Can J Gastroenterol; 2004 Jun; 18(6):381-6. PubMed ID: 15190393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of the fibrosis scores in patients with chronic hepatitis C associated with liver fibrosis and metabolic syndrome.
    Miyaaki H; Ichikawa T; Taura N; Miuma S; Shibata H; Isomoto H; Takeshima F; Nakao K
    Intern Med; 2011; 50(11):1137-41. PubMed ID: 21628926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with Type 2 diabetes in South China.
    Yi M; Chen RP; Yang R; Chen H
    Diabet Med; 2017 Apr; 34(4):505-513. PubMed ID: 27334577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Waiting List Mortality and Transplant Rates for NASH Cirrhosis When Compared With Cryptogenic, Alcoholic, or AIH Cirrhosis.
    Thuluvath PJ; Hanish S; Savva Y
    Transplantation; 2019 Jan; 103(1):113-121. PubMed ID: 29985186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of type 2 diabetes mellitus and chronic liver disease: a retrospective study of the association of two increasingly common diseases in Mexico.
    Kobashi-Margáin RA; Gutiérrez-Grobe Y; Ponciano-Rodríguez G; Uribe M; Méndez-Sánchez N
    Ann Hepatol; 2010; 9(3):282-8. PubMed ID: 20720269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography.
    Harman DJ; Ryder SD; James MW; Wilkes EA; Card TR; Aithal GP; Guha IN
    Aliment Pharmacol Ther; 2018 Feb; 47(4):504-515. PubMed ID: 29210096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryptogenic cirrhosis: metabolic liver disease due to insulin resistance.
    De BK; Mani S; Mandal SK; Mondal SS; Bhattacharya R; Pramanik AB; Sau D; Bhattacharjee K; Joardar S
    Indian J Med Sci; 2010 Nov; 64(11):508-19. PubMed ID: 23051943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.